nicotinell icemint lyfjatyggigúmmí 4 mg
haleon denmark aps - nicotinum polacrillin - lyfjatyggigúmmí - 4 mg
nicotinell spearmint lyfjatyggigúmmí 2 mg
haleon denmark aps - nicotinum resin-komplex - lyfjatyggigúmmí - 2 mg
nicorette whitemint lyfjatyggigúmmí 2 mg
mcneil denmark aps - nicotinum resin-komplex - lyfjatyggigúmmí - 2 mg
nicotinell icemint lyfjatyggigúmmí 2 mg
haleon denmark aps - nicotinum polacrillin - lyfjatyggigúmmí - 2 mg
apidra
sanofi-aventis deutschland gmbh - glúlísíninsúlín - sykursýki - lyf notuð við sykursýki - meðferð hjá fullorðnum, unglingum og börnum, sex ára eða eldri með sykursýki, þar sem meðferð með insúlíni er krafist.
xtandi
astellas pharma europe b.v. - enzalutamíð - blöðruhálskirtli - innkirtla meðferð - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
nicotinell mint munnsogstafla 1 mg
haleon denmark aps - nicotinum bítartrat - munnsogstafla - 1 mg
nicorette invisi forðaplástur 10 mg/16 klst.
mcneil denmark aps - nicotinum - forðaplástur - 10 mg/16 klst.
nicorette invisi forðaplástur 15 mg/16 klst.
mcneil denmark aps - nicotinum - forðaplástur - 15 mg/16 klst.
nicorette invisi forðaplástur 25 mg/16 klst.
mcneil denmark aps - nicotinum - forðaplástur - 25 mg/16 klst.